Update Your Colistin and Polymyxin B Protocols

You'll see more focus on optimizing polymyxin antibiotics...due to new guidelines from the Infectious Diseases Society of America and others.

IV colistin (polymyxin E) and polymyxin B have been around for decades. But nephrotoxicity concerns limit their use.

Now we're reaching for polymyxins more often due to increases in multidrug-resistant (MDR) gram-negative organisms, such as carbapenem-resistant Enterobacteriaceae or some Pseudomonas or Acinetobacter.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals